Results 121 to 130 of about 3,980 (188)

Plain language summary: 5-year results from the CROWN study of lorlatinib vs crizotinib in non-small-cell lung cancer. [PDF]

Future Oncol
Solomon BJ, Liu G, Felip E, K Mok TS, Soo RA, Mazieres J, Shaw AT, Marinis F, Goto Y, Wu YL, Kim DW, Martini JF, Messina R, Paolini J, Polli A, Thomaidou D, Toffalorio F, Bauer TM.   +17 more
europepmc   +1 more source

Complete and durable regression of leptomeningeal involvement during lorlatinib treatment in a patient with lung cancer. [PDF]

Anticancer Drugs
Guaitoli G, Martinelli E, Trudu L, Desideri I, Mortini P, Greco S, Bruni A, Greto D, Pecchioli G, Chiavelli C, Dominici M, Bertolini F.   +11 more
europepmc   +1 more source

Synthesis and structure-activity relationship of liposomal substrates for phospholipase A(2) [PDF]

, 2011
Clausen, Mads Hartvig, Viart, Helene Marie-France   +1 more
core  

Combatting resistance: natural products as tools to drive the discovery of untapped antibiotic targets.

Chem Commun (Camb)
Hedges MR, Di Carlo CM, Wuest WM.
europepmc   +1 more source

A comprehensive functional atlas of ALK kinase domain variants reveals resistance landscape to ALK inhibitors. [PDF]

Genome Biol
Oh HC, Han Y, Chang Y, Kim HH.
europepmc   +1 more source

Conformationally rigid histone deacetylase inhibitors correct DF508-CFTR protein function [PDF]

, 2011
Balch, William E., Ghadiri, M. Reza, Hutt, Darren M., Leman, Luke J., Maryanoff, Bruce E., Montero, Ana, Olsen, Christian Adam, Vickers, Chris J.   +7 more
core  

Retreatment of patients with chronic hepatitis C, subtype 3a, and cirrhosis, who previously failed a regimen containing second-generation NS5A inhibitors with sofosbuvir + glecaprevir/pibrentasvir and ribavirin for 16-24 weeks. [PDF]

J Virol
Fedorchenko SV, Klimenko Z, Martynovich T, Solianyk I, Suprunenko T.   +4 more
europepmc   +1 more source

From Pseudocyclic to Macrocyclic Ionophores: Strategies toward the Synthesis of Cyclic Monensin Derivatives. [PDF]

J Org Chem
Sulik M, Graniczny R, Janczak J, Kłopotowska D, Wietrzyk J, Huczyński A.   +5 more
europepmc   +1 more source

Lorlatinib atypical safety profile in ALK-positive aNSCLC: tips for management from an Italian expert panel. [PDF]

Future Oncol
Ardizzoni A, Cortinovis D, Gori B, Nuzzo A, Pasello G, de Marinis F.   +5 more
europepmc   +1 more source

Versatile dehydrogenation of carbonyls enabled by an iodine(III) reagent.

Chem Commun (Camb)
Botlik BB, Finkelstein P, Paschke AK, Reisenbauer JC, Morandi B.   +4 more
europepmc   +1 more source